Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).

@article{ForeroTorres2010PhaseIT,
  title={Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).},
  author={Andres Forero-Torres and J. C. Shah and Tina E Wood and James Posey and Ronda Carlisle and Catherine Copigneaux and Feng Roger Luo and Slawomir Wojtowicz-Praga and Ivor J Percent and Mansoor Saleh},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={2010},
  volume={25 1},
  pages={13-9}
}
BACKGROUND TRA-8 is a murine agonist monoclonal antibody to death receptor 5 (DR5), which is able to trigger apoptosis in DR5 positive human tumor cells without the aid of crosslinking. It has demonstrated cytotoxicity in vitro and in vivo antitumor efficacy to a wide range of solid tumors in murine xenograft models. Tigatuzumab is a humanized IgG1 monoclonal antibody derived from TRA-8. METHODS A phase I trial of tigatuzumab in patients with relapsed/refractory carcinomas (n = 16) or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

AMG 655 , a fully human agonistic antibody against death receptor 5 , enhances the anti - tumor activity of gemcitabine in MiaPaCa 2 = T 2 , a pancreatic cancer model

  • P Kaplan-Lefko, T Bush, B Belmontes
  • AACR Meeting Abstracts
  • 2008

Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts

  • J Li, B Tang, J Cheng
  • AACR Meeting Abstracts
  • 2007

Similar Papers

Loading similar papers…